RYBELSUS^® (semaglutide tablets) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus:

• as monotherapy when metformin is considered inappropriate due to intolerance or contraindications
• in combination with other medicinal products for the treatment of diabetes (see clinical trials in the Product Monograph for patient populations and drug combinations tested)

Click here for additional safety information and for a link to the Product Monograph discussing:

• Contraindications in personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), and pregnancy or breastfeeding
• A serious warning on risk of thyroid C-cell tumours
• Other relevant warnings and precautions relating to hypoglycemia with concomitant use of insulin secretagogues or insulin, driving and operating machinery, CV effects (increased heart rate; PR interval prolongation), pancreatitis, hypersensitivity, diabetic retinopathy (in patients with history of disease, monitor for progression), renal insufficiency (severe GI adverse reactions warrant monitoring of renal function; acute renal failure and worsening of chronic renal failure have been reported), fertility, and hepatic impairment
• Conditions of clinical use, adverse reactions, drug interactions, and dosing instructions

Watch video now